Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Arqule Inc (ARQL)

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,161,601
  • Shares Outstanding, K 109,585
  • Annual Sales, $ 25,760 K
  • Annual Income, $ -15,480 K
  • 60-Month Beta 2.27
  • Price/Sales 47.00
  • Price/Cash Flow N/A
  • Price/Book 16.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.10
  • Number of Estimates 4
  • High Estimate -0.08
  • Low Estimate -0.11
  • Prior Year 0.05
  • Growth Rate Est. (year over year) -300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.20 +29.51%
on 06/17/19
12.22 -13.09%
on 07/05/19
+2.42 (+29.51%)
since 06/14/19
3-Month
5.76 +84.37%
on 04/29/19
12.22 -13.09%
on 07/05/19
+3.97 (+59.70%)
since 04/16/19
52-Week
2.23 +376.23%
on 12/21/18
12.22 -13.09%
on 07/05/19
+5.33 (+100.76%)
since 07/16/18

Most Recent Stories

More News
ARQL Crosses Above Average Analyst Target

In recent trading, shares of ArQule Inc. have crossed above the average analyst 12-month target price of $11.20, changing hands for $11.44/share.

ARQL : 10.62 (+0.19%)
ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase...

ARQL : 10.62 (+0.19%)
Do Options Traders Know Something About ArQule (ARQL) Stock We Don't?

Investors need to pay close attention to ArQule (ARQL) stock based on the movements in the options market lately.

ARQL : 10.62 (+0.19%)
ArQule (ARQL) Catches Eye: Stock Jumps 8.1%

ArQule (ARQL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

ARQL : 10.62 (+0.19%)
NEOS : 1.37 (-3.52%)
ArQule Announces Pricing of $90 Million Public Offering of Common Stock

ArQule, Inc. (Nasdaq:ARQL) today announced the pricing of an underwritten public offering of 9,250,000 shares of its common stock at a price to the public of $9.75 per share. ArQule has granted the underwriters...

ARQL : 10.62 (+0.19%)
ArQule Announces Commencement of Proposed Public Offering of Common Stock

ArQule, Inc. (Nasdaq: ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with...

ARQL : 10.62 (+0.19%)
ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference

ArQule, Inc. (Nasdaq:ARQL), today announced it will present preliminary results from the company's phase 1/2 study of its pan-AKT inhibitor, miransertib (ARQ 092), in patients with PIK3CA-related...

ARQL : 10.62 (+0.19%)
ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA)

--Conference call and webcast with ArQule management and Dr. Jennifer Woyach, Principal Investigator, to be held Friday, June 14, 2018 at 8:00 a.m. EDT

ARQL : 10.62 (+0.19%)
ArQule to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Dr. Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 20th Annual B. Riley FBR Institutional Investor Conference...

ARQL : 10.62 (+0.19%)
ArQule to Present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at...

ARQL : 10.62 (+0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ARQL with:

Business Summary

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage...

See More

Key Turning Points

2nd Resistance Point 10.91
1st Resistance Point 10.76
Last Price 10.62
1st Support Level 10.44
2nd Support Level 10.27

See More

52-Week High 12.22
Last Price 10.62
Fibonacci 61.8% 8.40
Fibonacci 50% 7.23
Fibonacci 38.2% 6.05
52-Week Low 2.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar